# Clinicopathological features and diagnostic challenges of hepatic epithelioid angiomyolipoma: a retrospective analysis of 27 cases

**Authors:** Erming Cai, Hongzhen Wei, Yizhuo Shi, Shiran Sun, Chidan Wan

PMC · DOI: 10.3389/fmed.2026.1729519 · Frontiers in Medicine · 2026-02-09

## TL;DR

This study analyzes 27 cases of a rare liver tumor to understand its features and challenges in diagnosis and treatment.

## Contribution

Provides a systematic analysis of hepatic epithelioid angiomyolipoma through a single-center cohort study.

## Key findings

- Most patients were asymptomatic, and preoperative imaging rarely led to correct diagnosis.
- All tumors were positive for HMB-45 and Melan-A, aiding in definitive diagnosis.
- Surgical resection was the primary treatment due to the tumor's potential for malignancy.

## Abstract

Hepatic epithelioid angiomyolipoma, a rare mesenchymal tumor, poses significant diagnostic challenges due to its rarity and non-specific presentation. Existing literature is dominated by case reports, limiting a systematic understanding of its clinicopathological profile. Therefore, further in-depth research is of great significance for elucidating the nature and clinical features of this disease.

To define the clinicopathological characteristics, diagnostic features, and management outcomes of Hepatic epithelioid angiomyolipoma by analyzing a single-center cohort.

We retrospectively analyzed 27 patients diagnosed with hepatic epithelioid angiomyolipoma at a single institution between April 2019 and November 2024. We collected and examined data on clinical presentation, laboratory findings, imaging results from ultrasound, computed tomography, and magnetic resonance imaging, as well as histopathological and immunohistochemical features.

The cohort was predominantly female (88.9%; 24/27), with a mean age of 44.2 years, and most patients (81.5%; 22/27) were asymptomatic. Preoperative imaging frequently mimicked other liver tumors, resulting in a correct preoperative diagnosis in only 3.7% of cases. Pathologically, all tumors tested were positive for HMB-45 (100%) and Melan-A (100%). Surgical resection was the primary treatment (96.3%). Tissue biopsy combined with microwave ablation was performed in 3.7% (1/27) of the patients. 27 cases were diagnosed as typical hepatic epithelioid angiomyolipoma.

Hepatic epithelioid angiomyolipoma presents with non-specific clinical and radiological features, making preoperative diagnosis challenging and often leading to misdiagnosis as other common liver tumors. Definitive diagnosis depends on histopathological and immunohistochemical analysis. Surgical resection remains the primary treatment due to the tumor’s malignant potential. A high index of suspicion and reliance on pathological confirmation are crucial for accurate management of this rare tumor.

## Linked entities

- **Proteins:** PMEL (premelanosome protein)

## Full-text entities

- **Genes:** MLANA (melan-A) [NCBI Gene 2315] {aka MART-1, MART1}, GPC3 (glypican 3) [NCBI Gene 2719] {aka DGSX, GTR2-2, MXR7, OCI-5, SDYS, SGB}, DES (desmin) [NCBI Gene 1674] {aka CDCD3, CSM1, CSM2, LGMD1D, LGMD1E, LGMD2R}, TSC1 (TSC complex subunit 1) [NCBI Gene 7248] {aka LAM, TSC}, S100A1 (S100 calcium binding protein A1) [NCBI Gene 6271] {aka S100, S100-alpha, S100A}, MUC16 (mucin 16, cell surface associated) [NCBI Gene 94025] {aka CA125}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}, CD34 (CD34 molecule) [NCBI Gene 947], SMN1 (survival of motor neuron 1, telomeric) [NCBI Gene 6606] {aka BCD541, GEMIN1, SMA, SMA1, SMA2, SMA3}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, TSC2 (TSC complex subunit 2) [NCBI Gene 7249] {aka LAM, PPP1R160, TSC4}
- **Diseases:** hepatic neoplasms (MESH:D008113), FNH (MESH:D020518), necrosis (MESH:D009336), tuberous sclerosis complex (MESH:D014402), immune dysregulation (OMIM:614878), HCC (MESH:D006528), systemic (MESH:D015619), abnormal liver enzymes (MESH:D056486), PEComa (MESH:D054973), abdominal distension (MESH:D000007), teratoma (MESH:D013724), hepatic adenoma (MESH:C564190), metastases (MESH:D009362), LAM (MESH:D018192), anemia (MESH:D000740), Renal Tumours (MESH:D007680), proteinuria (MESH:D011507), renal AMLs (MESH:D006030), mesenchymal tumor (MESH:C535700), cholangiocarcinoma (MESH:D018281), anorexia (MESH:D000855), edema (MESH:D004487), Digestive System Tumors (MESH:D004067), abdominal pain (MESH:D015746), hepatic tumors (MESH:D009369), EAML (MESH:D018207), chronic liver disease (MESH:D008107)
- **Chemicals:** eosin (MESH:D004801), Gd-EOB-DTPA (MESH:C073590), paraformaldehyde (MESH:C003043), lipid (MESH:D008055), 18F-FDG (MESH:D019788), everolimus (MESH:D000068338), hematoxylin (MESH:D006416), H&amp;E (MESH:D006371), PIVKA-II (-), sirolimus (MESH:D020123), bilirubin (MESH:D001663), paraffin (MESH:D010232)
- **Species:** Homo sapiens (human, species) [taxon 9606], hepatitis C virus [taxon 11103]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12926390/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12926390/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC12926390/full.md

---
Source: https://tomesphere.com/paper/PMC12926390